NCT07061288View on ClinicalTrials.gov

A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia

PHASE1RecruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

September 3, 2025

Primary Completion Date

June 21, 2027

Study Completion Date

October 15, 2027

Conditions
Schizophrenia
Interventions
DRUG

KarXT

Specified dose on specified days

Trial Locations (8)

30030

RECRUITING

CenExel iResearch, LLC, Decatur

30331

RECRUITING

Atlanta Center for Medical Research, Atlanta

33016

RECRUITING

Innovative Clinical Research, Inc., Miami Lakes

33024

RECRUITING

Research Centers of America ( Hollywood ), Hollywood

60640

RECRUITING

Uptown Research Institute, Chicago

78754

NOT_YET_RECRUITING

Local Institution - 0006, Austin

90720-3118

RECRUITING

Collaborative Neuroscience Research, LLC, Los Alamitos

08053

RECRUITING

Hassman Research Institute Marlton Site, Marlton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT07061288 - A Study to Evaluate the Dose Levels, Safety, and Drug Levels of Single KarXT Intramuscular Injection in Participants With Schizophrenia | Biotech Hunter | Biotech Hunter